IPCALAB:NSE
IPCA Laboratories Ltd
₹1,912.00
arrow_downward
-1.36%(-26.40) 1D
Oct 9, 3:30:00 PM GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IPCALAB...
Open
₹1,942.90
High
₹1,952.50
Low
₹1,905.00
Mkt. cap
485.08B
Avg. vol.
246.80K
Volume
94.28K
Dividend
0.31%
Quarterly dividend
₹1.50
Ex-dividend date
Aug 7, 2026
P/E ratio
37.03
52-wk high
₹2,038.00
52-wk low
₹1,251.60
EPS
₹51.63
Shares outstanding
126.35M
No. of employees
17K
Open
₹1,942.90
High
₹1,952.50
Low
₹1,905.00
Mkt. cap
485.08B
Avg. vol.
246.80K
Volume
94.28K
Dividend
0.31%
Quarterly dividend
₹1.50
Ex-dividend date
Aug 7, 2026
P/E ratio
37.03
52-wk high
₹2,038.00
52-wk low
₹1,251.60
EPS
₹51.63
Shares outstanding
126.35M
No. of employees
17K
News stories
From web sources and news partners
Seeking Alpha
·
14 minutes ago
Why The Negative Market Breadth Is Not A Negative Factor This Time (NYSEARCA:SPY)
El Dorado News-Times
·
34 minutes ago
Wall Street finishes its record-setting week with gains
24/7 Wall St.
·
1 hour ago
Why "VOO and Chill" Lost Money for 8 Straight Years: What $100,000 in the S&P 500 Did From 2000 to 2008
Nasdaq
·
20 hours ago
WISeSat.Space Holdings Corp. Rings the Opening Bell
Profile
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients, covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.
Ipca is one of the largest global suppliers of the antimalarials hydroxychloroquine and chloroquine, as well as of APIs such as atenolol, chlorthalidone, losartan and metoprolol. Since 2023, it has held a majority stake in Unichem Laboratories. The company is listed on the BSE and the National Stock Exchange of India, and reported consolidated revenue of ₹9,646 crore in the financial year ended 31 March 2026. Wikipedia
About IPCA Laboratories Ltd